Credits: Canva
As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.
As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."
The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.
The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.
Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.
As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.
A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.
TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."
Credit: AI-generated image
The Maharashtra Food and Drug Administration (FDA) recently banned the sale, distribution, and use of several fairness creams after dangerous levels of toxic heavy metals, including lead and mercury, were found in the products.
Among the products, one named Goree Beauty Cream is of Pakistani origin. The product was reportedly being sold unlawfully in the state.
The FDA labelled the products “Not of Standard Quality” (NSQ), warning consumers against using them as prolonged exposure to heavy metals present in the products can lead to serious health complications associated with skin, kidneys as well as the nervous system.
According to the Maharashtra FDA, the following cosmetic products have been declared unsafe:
Officials also noted that the products lacked mandatory information like the manufacturer's complete details, batch number, manufacturing date, and expiry date, raising concerns over their authenticity and safety.
If used repeatedly, these toxic substances may be absorbed through the skin, allowing them to accumulate in the body over time.
Excessive exposure to mercury can cause:
The risk increases with prolonged use, particularly when the products are used on a daily basis over months or years.
Also read: Australia Reports More H5 Bird Flu Cases: Does It Have Pandemic Potential?
On the other hand, lead exposure can cause:
Even if lead accumulates in the body in small amounts, its repeated use may pose long-term health risks.
Sometimes, mercury is illegally added to skin-lightening products as it suppresses melanin production, temporarily making the skin appear lighter. However, this skin-lightening effect comes at the cost of significant health risks.
Lead may contaminate cosmetic products through poor-quality raw materials or unsafe manufacturing processes. Neither ingredient should be intentionally present in cosmetic creams sold for routine use.
International health agencies have repeatedly warned against skin-lightening creams containing mercury.
In June 2026, the US FDA again cautioned consumers not to use over-the-counter skin-lightening products found to contain mercury or hydroquinone because of the risk of kidney injury, neurological damage, and permanent skin problems.
The Maharashtra FDA's crackdown highlights the hidden dangers of unregulated and illegal fairness creams that contain harmful ingredients.
While these products may promise lighter skin, the presence of toxic heavy metals such as mercury and lead can expose users to potentially irreversible health damage. Consumers are advised to read the labels carefully before purchasing any skincare products that promise complexion-altering effects.
Credit: AI-generated image
Usually, the most telling symptoms of Alzheimer's disease surface in old age. With no cure and limited ways to detect it early, it is challenging to treat and manage Alzheimer's. However, a recent study says that a new blood test can help in diagnosing Alzheimer's early.
A new blood test that measures tiny loops of genetic material in the bloodstream may be able to predict when Alzheimer's disease symptoms are likely to appear, offering hope for earlier intervention of the neurodegenerative disease and more effective clinical trials.
A study funded by the U.S. National Institutes of Health (NIH) says that a specific group of blood-based biomarkers known as circular RNAs could help identify people who are on the brink of developing Alzheimer's symptoms, even before memory loss or cognitive decline becomes apparent.
The current blood tests for Alzheimer's have been made after significant progress in recent years, particularly by detecting proteins linked to amyloid plaques, one of the disease's primary characteristics features.
However, these tests may present positive results for many years, even decades, before symptoms like declining memory and thinking appear. It makes it difficult for doctors to predict when the disease will actually begin affecting the patient’s quality of life.
The newly developed blood test could fill that existing gap. Scientists found that elevated levels of a set of 34 circular RNAs in blood were strongly associated with future symptoms of the onset.
According to the study, those with higher circRNA levels were nearly three times more likely to develop Alzheimer's symptoms compared with those with lower levels.
The changes appeared approximately two to four years before symptoms emerged, making them a valuable diagnostic test for predicting disease progression.
The discovery could transform existing Alzheimer's research by helping scientists identify participants who are most likely to develop symptoms during a clinical trial.
Finding out when symptoms are likely to begin would allow researchers to introduce preventive therapies at the stage when they are most likely to be effective and better evaluate whether experimental treatments can delay cognitive decline.
The current methods to assess Alzheimer's include PET brain scans, which are expensive and not widely available. Lumbar punctures (spinal taps), an invasive method, is also used.
Compared to the existing methods to screen Alzheimer's, a blood test is easier to perform, less invasive, more affordable and more accessible, especially if validated for widespread clinical use.
If doctors can ascertain the symptoms early, patients and their families can, patients’ families can plan future care and support. They can use the time to make financial and legal decisions while the person is still cognitively healthy. Patients can also adopt lifestyle changes that may help maintain brain health.
Researchers however stressed that the new circRNA test is still in the research stage and requires further validation in larger and more diverse populations before it can be adopted in clinical practice.
Credit: AI-generated image
The World Health Organization (WHO) has issued a global medical product alert after identifying falsified batches of the cancer medicine DARZALEX (daratumumab). It also issued a warning that the counterfeit products could cause serious health risks to patients and disrupt the treatment process.
The WHO issued an alert against the circulation of falsified DARZALEX (daratumumab). The incident came to light in May and June 2026. According to the WHO, the falsified injections were found in the Maldives and Mexico after being supplied by unauthorised distributors.
In at least one reported case, hospitals received fake medication, prompting international concern over gaps in the pharmaceutical supply chain.
DARZALEX (daratumumab) is an antibody that is used to treat multiple myeloma, cancer of plasma cells in the bone marrow, as well as amyloid light-chain (AL) amyloidosis, a rare blood disorder.
The drug plays a crucial role in the treatment of various types of cancer. That is why the WHO said that the circulation of its compromised version could cause delayed therapy, treatment failure, and potentially life-threatening consequences.
Read more: Why Sustainable Weight Loss Requires More Than Cutting Calories
WHO said the fake products deliberately misrepresent their identity, composition, or source. The manufacturer, Janssen, confirmed that the batch numbers MYS7381 and STV1K01 are not valid, and any DARZALEX product bearing these batch numbers should be considered falsified and must not be used.
The Maldives Food and Drug Authority also reported visible particulate matter inside vials from one of the counterfeit batches.
The UN health agency has urged national regulatory health bodies, healthcare providers, wholesalers, and distributors to strengthen security across the pharmaceutical supply chains to prevent the infiltration of counterfeits.
It also advised countries to closely monitor unregulated pharmaceutical markets, where counterfeit medicines are more likely to circulate.
Read more: ICMR & IIT Bombay Create Placenta-On-Chip To Study Pregnancy Disorders & Drug Safety
WHO issued precautionary measures to avoid purchasing falsified medications:
The latest warning adds to a growing list of WHO medical product alerts involving counterfeit cancer medicines.
In recent years, the WHO has issued alerts for various falsified cancer drugs including IMFINZI (durvalumab), IBRANCE (palbociclib) and DEFITELIO (defibrotide), highlighting the growing threat of counterfeit medicines that could disrupt life-saving treatment courses.
The WHO estimates that more than one in ten medical products in underdeveloped and developed countries are either substandard or falsified, making poor-quality medicines one of the world's major public health challenges.
© 2024 Bennett, Coleman & Company Limited